In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price target, which represents a potential upside …
In a research report issued August 11, Roth Capital analyst Debjit Chattopadhyay reinstated a Buy rating on Nektar Therapeutics (NKTR), and introduced a $19 price target. The following …
